Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7132570 | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Dec, 2023
(4 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE37516 | CEPHALON | Acetamide derivative having defined particle size |
Oct, 2014
(9 years ago) | |
USRE37516 (Pediatric) | CEPHALON | Acetamide derivative having defined particle size |
Apr, 2015
(9 years ago) | |
US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(4 months ago) | |
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(a month from now) | |
US7132570 (Pediatric) | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Jun, 2024
(a month from now) |
Market Authorisation Date: 15 June, 2007
Treatment: Improved wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder
Dosage: TABLET;ORAL